Reviews
Immune checkpoint inhibitor-related myositis: from pathophysiology to treatment
C. Sundarrajan1, S. Bhai2, M.M. Dimachkie3
- Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA.
- Department of Neurology, UT Southwestern Medical Center, Dallas, and Neuromuscular Center, Institute for Exercise and Environmental Medicine, Texas Health Presbyterian, Dallas, TX, USA. salman.bhai@utsouthwestern.edu
- Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
CER16418
2023 Vol.41, N°2
PI 0379, PF 0385
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 36622122 [PubMed]
Received: 01/12/2022
Accepted : 09/12/2022
In Press: 03/01/2023
Published: 01/03/2023
Abstract
With rapid advances in immuno-oncology, immune checkpoint inhibitors (ICIs) are increasingly used for a broad array of malignancies. This has led to a novel spectrum of adverse effects including ICI-related myositis, a potentially life-threatening neuromuscular complication that must be diagnosed and treated promptly. Significant gaps exist in the current understanding of ICI-related myositis due to the rarity of the condition and the lack of evidence-based guidelines, prompting the need to synthesize the most relevant and recent published works in the field. This review provides a broad overview of ICI-related myositis with an emphasis on pathophysiology, epidemiology, clinical features, workup, management and future directions.
